528
Participants
Start Date
November 9, 2018
Primary Completion Date
August 16, 2021
Study Completion Date
January 2, 2022
CPI 613, mFolfirinox
CPI-613: 500mg/m2, IV infusion at a rate of 4mL/min via a central venous port. mFolfirinox: given immediately after CPI-613 administration
Folfirinox
Folfirinox
Hôpital Erasme, Brussels
Korea University Anam Hospital, Seoul
UZ Leuven, Leuven
Severance Hospital - Yonsei Cancer Center, Seoul
Samsung Medical Center, Seoul
National Cancer Center, Seoul
New York University Langone Medical Center, New York
Stony Brook University Hospital, Stony Brook
Seoul National University Bundang Hospital, Seongnam-si
Roswell Park Cancer Institute, Buffalo
University of Pittsburgh-Hillman cancer ceter, Pittsburgh
Ajou University Hospital, Suwon
Georgetown University Medical Center, Washington D.C.
Gachon University Gil Hospital, Incheon
Inha University Hospital, Incheon
University of Virginia Cancer Center - Emily Couric Clinical Cancer Center, Charlottesville
VCU Massey Cancer Center, Richmond
Blue Ridge Cancer Care, Roanoke
Wake Forest Baptist Health, Winston-Salem
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Levine cancer Institute, Charlotte
CHRU Brest - Hôpital Morvan, Brest
Rambam Medical Center, Haifa
Mayo Clinic Hospital, Jacksonville
Mount Sinai Medical Center, Miami Beach
CHU Hopitaux de Bordeaux - Hôpital Saint-André, Pessac
L'ICM, Institut régional du Cancer de Montpellier, Montpellier
Centre Eugène Marquis, Rennes
Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center-Henry-Joyce Cancer Clinic, Nashville
Hillel Yaffe Medical Center, Hadera
Kyungpook National University Chilgok Hospital, Daegu
Sanz Medical Center - Laniado Hospital, Netanya
CHU de Nantes - Hôpital Nord Laennec, Nantes
Cleveland Clinic - Taussig Cancer Center, Cleveland
University Hospitals - Seidman Cancer Center, Cleveland
Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH, Bochum
University of Cincinnati Cancer Institute, Cincinnati
University of Micihgan, Ann Arbor
Karmanos cancer Center, Detroit
Seoul National University Hospital, Busan
The Chaim Sheba Medical Center - Sheba Cancer Research Center (SCRC), Ramat Gan
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy
Mayo Clinic Cancer Center (MCCC), Rochester
University of Chicago, Harvey
Northwestern Memorial Hospital - Arkes Family Pavilion, Chicago
Tel Aviv Sourasky Medical Center, Tel Aviv
Washington University, St Louis
The University of Kansas Cancer Center - Clinical Research Center - Fairway Office Park, Fairway
Assaf-Harofeh Medical Center, Ẕerifin
Universitaetsklinikum Tuebingen, Tübingen
SLK-Kliniken Heilbronn GmbH, Heilbronn
The University of Texas MD Anderson Cancer Center, Houston
Huntsman cancer Institute, Salt Lake City
Banner MD Anderson Cancer Center, Gilbert
The University of Arizona Cancer Center, Tucson
Centre Hospitalier Départemental Vendée - Hôpital de la Roche-sur-Yon, La Roche-sur-Yon
CHU de Poitiers, Poitiers
University of New Mexico Cancer Center, Albuquerque
Comprehensive Cancer centers of Nevada, Las Vegas
USC Norris Comprehensive Cancer Center, Los Angeles
UCLA Medical Center, Los Angeles
City of Hope, Duarte
Shaare Zedek Medical Center, Jerusalem
Hôpital Beaujon, Clichy
Pacific Hematology Oncology Associates, San Francisco
Gustave Roussy Cancer Campus Grand Paris (Institut de Cancerologie Gustave-Roussy), Villejuif
Oregon Health and Science University, Portland
Seattle Cancer Care Alliance, Seattle
Smilow Cancer Hospital at Yale-New Haven, New Haven
University of Massachusetts Memorial Medical Center, Worcester
Englewood Hospital and Medical Center, Englewood
Atlantic Health System, Morristown
The Catholic University of Korea - Seoul St. Mary's Hospital (Kangnam St. Mary's Hospital), Seocho
Seoul National University Hospital, Seoul
Lead Sponsor
Cornerstone Pharmaceuticals
INDUSTRY